Clinico-biological features of T-cell acute lymphoblastic leukemia with fusion proteins.

Adolescent Adult Child Child, Preschool Female Humans Infant Male Middle Aged Young Adult Oncogene Proteins, Fusion / genetics Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis Prognosis T-Lymphocytes / pathology

Journal

Blood cancer journal
ISSN: 2044-5385
Titre abrégé: Blood Cancer J
Pays: United States
ID NLM: 101568469

Informations de publication

Date de publication:
26 01 2022
Historique:
received: 02 09 2021
accepted: 06 01 2022
revised: 01 01 2022
entrez: 27 1 2022
pubmed: 28 1 2022
medline: 23 2 2022
Statut: epublish

Résumé

T-cell acute lymphoblastic leukemias (T-ALL) represent 15% of pediatric and 25% of adult ALL. Since they have a particularly poor outcome in relapsed/refractory cases, identifying prognosis factors at diagnosis is crucial to adapting treatment for high-risk patients. Unlike acute myeloid leukemia and BCP ALL, chromosomal rearrangements leading to chimeric fusion-proteins with strong prognosis impact are sparsely reported in T-ALL. To address this issue an RT-MPLA assay was applied to a consecutive series of 522 adult and pediatric T-ALLs and identified a fusion transcript in 20% of cases. PICALM-MLLT10 (4%, n = 23), NUP214-ABL1 (3%, n = 19) and SET-NUP214 (3%, n = 18) were the most frequent. The clinico-biological characteristics linked to fusion transcripts in a subset of 235 patients (138 adults in the GRAALL2003/05 trials and 97 children from the FRALLE2000 trial) were analyzed to identify their prognosis impact. Patients with HOXA trans-deregulated T-ALLs with MLLT10, KMT2A and SET fusion transcripts (17%, 39/235) had a worse prognosis with a 5-year EFS of 35.7% vs 63.7% (HR = 1.63; p = 0.04) and a trend for a higher cumulative incidence of relapse (5-year CIR = 45.7% vs 25.2%, HR = 1.6; p = 0.11). Fusion transcripts status in T-ALL can be robustly identified by RT-MLPA, facilitating risk adapted treatment strategies for high-risk patients.

Identifiants

DOI: 10.1038/s41408-022-00613-9 PMID: 35082269 PMC: PMC8791998
pubmed: 35082269
doi: 10.1038/s41408-022-00613-9
pii: 10.1038/s41408-022-00613-9
pmc: PMC8791998
doi:

Substances chimiques

NUP214-ABL1 fusion protein, human 0
Oncogene Proteins, Fusion 0
PICALM-MLLT10 fusion protein, human 0
SET-NUP214 fusion protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

14

Informations de copyright

© 2022. The Author(s).

Références

Ferrando AA, Neuberg DS, Staunton J, Loh ML, Huard C, Raimondi SC, et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 2002;1:75–87.
pubmed: 12086890 doi: 10.1016/S1535-6108(02)00018-1
Asnafi V, Radford-Weiss I, Dastugue N, Bayle C, Leboeuf D, Charrin C, et al. CALM-AF10 is a common fusion transcript in T-ALL and is specific to the TCRgammadelta lineage. Blood. 2003;102:1000–6.
pubmed: 12676784 doi: 10.1182/blood-2002-09-2913
Pui C-H, Yang JJ, Hunger SP, Pieters R, Schrappe M, Biondi A, et al. Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. J Clin Oncol. 2015;33:2938–48.
pubmed: 26304874 pmcid: 4567699 doi: 10.1200/JCO.2014.59.1636
Pui C-H, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008;371:1030–43.
pubmed: 18358930 doi: 10.1016/S0140-6736(08)60457-2
Hocking J, Schwarer AP, Gasiorowski R, Patil S, Avery S, Gibson J, et al. Excellent outcomes for adolescents and adults with acute lymphoblastic leukemia and lymphoma without allogeneic stem cell transplant: the FRALLE-93 pediatric protocol. Leuk Lymphoma. 2014;55:2801–7.
pubmed: 24528220 doi: 10.3109/10428194.2014.894191
Huguet F, Leguay T, Raffoux E, Thomas X, Beldjord K, Delabesse E, et al. Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 Study. JCO. 2009;27:911–8.
doi: 10.1200/JCO.2008.18.6916
Graux C, Cools J, Michaux L, Vandenberghe P, Hagemeijer A. Cytogenetics and molecular genetics of T-cell acute lymphoblastic leukemia: from thymocyte to lymphoblast. Leukemia. 2006;20:1496–510.
pubmed: 16826225 doi: 10.1038/sj.leu.2404302
Van Vlierberghe P, Pieters R, Beverloo HB, Meijerink JP. Molecular-genetic insights in paediatric T-cell acute lymphoblastic leukaemia. Br J Haematol. 2008;143:153–68.
pubmed: 18691165 doi: 10.1111/j.1365-2141.2008.07314.x
Fattizzo B, Rosa J, Giannotta JA, Baldini L, Fracchiolla NS. The Physiopathology of T- Cell Acute Lymphoblastic Leukemia: focus on Molecular Aspects. Front Oncol. 2020;10. https://doi.org/10.3389/fonc.2020.00273 .
Liu Y, Easton J, Shao Y, Maciaszek J, Wang Z, Wilkinson MR, et al. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat Genet. 2017;49:1211–8.
pubmed: 28671688 pmcid: 5535770 doi: 10.1038/ng.3909
Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature. 2012;481:157–63.
pubmed: 22237106 pmcid: 3267575 doi: 10.1038/nature10725
Belver L, Ferrando A. The genetics and mechanisms of T cell acute lymphoblastic leukaemia. Nat Rev Cancer. 2016;16:494–507.
pubmed: 27451956 doi: 10.1038/nrc.2016.63
Yang JJ, Park TS, Wan TSK. Recurrent Cytogenetic Abnormalities in Acute Myeloid Leukemia. In: Wan TSK, editors. Cancer Cytogenetics: Methods and Protocols. New York, NY:Springer; 2017. p. 223–45.
Schwab C, Harrison CJ. Advances in B-cell Precursor Acute Lymphoblastic Leukemia Genomics. Hemasphere. 2018;2:e53.
pubmed: 31723781 pmcid: 6746003 doi: 10.1097/HS9.0000000000000053
Chen B, Jiang L, Zhong M-L, Li J-F, Li B-S, Peng L-J, et al. Identification of fusion genes and characterization of transcriptome features in T-cell acute lymphoblastic leukemia. PNAS. 2018;115:373–8.
pubmed: 29279377 doi: 10.1073/pnas.1717125115
Matlawska-Wasowska K, Kang H, Devidas M, Wen J, Harvey RC, Nickl CK, et al. MLL rearrangements impact outcome in HOXA-deregulated T-lineage acute lymphoblastic leukemia: a Children’s Oncology Group Study. Leukemia. 2016;30:1909–12.
pubmed: 26952838 pmcid: 5014577 doi: 10.1038/leu.2016.60
Seki M, Kimura S, Isobe T, Yoshida K, Ueno H, Nakajima-Takagi Y, et al. Recurrent SPI1 (PU.1) fusions in high-risk pediatric T cell acute lymphoblastic leukemia. Nat Genet. 2017;49:1274–81.
pubmed: 28671687 doi: 10.1038/ng.3900
Van Vlierberghe P, van Grotel M, Tchinda J, Lee C, Beverloo HB, van der Spek PJ, et al. The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia. Blood. 2008;111:4668–80.
pubmed: 18299449 pmcid: 2343598 doi: 10.1182/blood-2007-09-111872
Brandimarte L, Pierini V, Di Giacomo D, Borga C, Nozza F, Gorello P, et al. New MLLT10 gene recombinations in pediatric T-acute lymphoblastic leukemia. Blood. 2013;121:5064–7.
pubmed: 23673860 doi: 10.1182/blood-2013-02-487256
Ben Abdelali R, Roggy A, Leguay T, Cieslak A, Renneville A, Touzart A, et al. SET-NUP214 is a recurrent γδ lineage-specific fusion transcript associated with corticosteroid/chemotherapy resistance in adult T-ALL. Blood. 2014;123:1860–3.
pubmed: 24449214 doi: 10.1182/blood-2013-08-521518
Asnafi V, Beldjord K, Boulanger E, Comba B, Le Tutour P, Estienne MH, et al. Analysis of TCR, pT alpha, and RAG-1 in T-acute lymphoblastic leukemias improves understanding of early human T-lymphoid lineage commitment. Blood. 2003;101:2693–703.
pubmed: 12446444 doi: 10.1182/blood-2002-08-2438
Delabesse E, Bernard M, Landman-Parker J, Davi F, Leboeuf D, Varet B, et al. Simultaneous SIL-TAL1 RT-PCR detection of all tal(d) deletions and identification of novel tal(d) variants. Br J Haematol. 1997;99:901–7.
pubmed: 9432040 doi: 10.1046/j.1365-2141.1997.4833286.x
Asnafi V, Beldjord K, Libura M, Villarese P, Millien C, Ballerini P, et al. Age-related phenotypic and oncogenic differences in T-cell acute lymphoblastic leukemias may reflect thymic atrophy. Blood. 2004;104:4173–80.
pubmed: 15054041 doi: 10.1182/blood-2003-11-3944
Ballerini P, Blaise A, Busson-Le Coniat M, Su XY, Zucman-Rossi J, Adam M, et al. HOX11L2 expression defines a clinical subtype of pediatric T-ALL associated with poor prognosis. Blood. 2002;100:991–7.
pubmed: 12130513 doi: 10.1182/blood-2001-11-0093
Bond J, Marchand T, Touzart A, Cieslak A, Trinquand A, Sutton L, et al. An early thymic precursor phenotype predicts outcome exclusively in HOXA-overexpressing adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study. Haematologica. 2016;101:732–40.
pubmed: 26944475 pmcid: 5013941 doi: 10.3324/haematol.2015.141218
Ruminy P, Marchand V, Buchbinder N, Larson T, Joly B, Penther D, et al. Multiplexed targeted sequencing of recurrent fusion genes in acute leukaemia. Leukemia. 2016;30:757–60.
pubmed: 26139430 doi: 10.1038/leu.2015.177
Deshpande AJ, Rouhi A, Lin Y, Stadler C, Greif PA, Arseni N, et al. The clathrin-binding domain of CALM and the OM-LZ domain of AF10 are sufficient to induce acute myeloid leukemia in mice. Leukemia. 2011;25:1718–27.
pubmed: 21681188 doi: 10.1038/leu.2011.153
Graux C, Stevens-Kroef M, Lafage M, Dastugue N, Harrison CJ, Mugneret F, et al. Heterogeneous patterns of amplification of the NUP214-ABL1 fusion gene in T-cell acute lymphoblastic leukemia. Leukemia. 2009;23:125–33.
pubmed: 18923437 doi: 10.1038/leu.2008.278
Hagemeijer A, Graux C. ABL1 rearrangements in T-Cell acute lymphoblastic leukemia. Genes Chromosom Cancer. 2010;49:299–308.
pubmed: 20073070
Forgione MO, McClure BJ, Yeung DT, Eadie LN, White DL. MLLT10 rearranged acute leukemia: incidence, prognosis, and possible therapeutic strategies. Genes, Chromosomes Cancer. 2020;59:709–21.
doi: 10.1002/gcc.22887
t(10;11)(p13–14;q14–21): A New Recurrent Translocation in T-Cell Acute Lymphoblastic Leukemias. Groupe Français de Cytogénétique Hématologique (GFCH). Genes Chromosom Cancer.1991;3:411–5.
Bond J, Bergon A, Durand A, Tigaud I, Thomas X, Asnafi V, et al. Cryptic XPO1-MLLT10 translocation is associated with HOXA locus deregulation in T-ALL. Blood. 2014;124:3023–5.
pubmed: 25377562 pmcid: 4224197 doi: 10.1182/blood-2014-04-567636
Romana SP, Radford-Weiss I, Ben Abdelali R, Schluth C, Petit A, Dastugue N, et al. NUP98 rearrangements in hematopoietic malignancies: a study of the Groupe Francophone de Cytogénétique Hématologique. Leukemia. 2006;20:696–706.
pubmed: 16467868 doi: 10.1038/sj.leu.2404130
Ben Abdelali R, Asnafi V, Petit A, Micol J-B, Callens C, Villarese P, et al. The prognosis of CALM-AF10-positive adult T-cell acute lymphoblastic leukemias depends on the stage of maturation arrest. Haematologica. 2013;98:1711–7.
pubmed: 23831922 pmcid: 3815171 doi: 10.3324/haematol.2013.086082
Lo Nigro L, Mirabile E, Tumino M, Caserta C, Cazzaniga G, Rizzari C, et al. Detection of PICALM-MLLT10 (CALM-AF10) and outcome in children with T-lineage acute lymphoblastic leukemia. Leukemia. 2013;27:2419–21.
pubmed: 23670296 doi: 10.1038/leu.2013.149
Dik WA, Brahim W, Braun C, Asnafi V, Dastugue N, Bernard OA, et al. CALM-AF10+ T-ALL expression profiles are characterized by overexpression of HOXA and BMI1 oncogenes. Leukemia. 2005;19:1948–57.
pubmed: 16107895 doi: 10.1038/sj.leu.2403891
Okada Y, Feng Q, Lin Y, Jiang Q, Li Y, Coffield VM, et al. hDOT1L Links Histone Methylation to Leukemogenesis. Cell. 2005;121:167–78.
pubmed: 15851025 doi: 10.1016/j.cell.2005.02.020
Okada Y, Jiang Q, Lemieux M, Jeannotte L, Su L, Zhang Y. Leukaemic transformation by CALM-AF10 involves upregulation of Hoxa5 by hDOT1L. Nat Cell Biol. 2006;8:1017–24.
pubmed: 16921363 pmcid: 4425349 doi: 10.1038/ncb1464
van Grotel M, Meijerink JP, Beverloo HB, Langerak AW, Buys-Gladdines JG, Schneider P, et al. The outcome of molecular-cytogenetic subgroups in pediatric T-cell acute lymphoblastic leukemia: a retrospective study of patients treated according to DCOG or COALL protocols. Haematologica. 2006;91:1212–21.
pubmed: 16956820
Chen L, Deshpande AJ, Banka D, Bernt KM, Dias S, Buske C, et al. Abrogation of MLL–AF10 and CALM–AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l. Leukemia. 2013;27:813–22.
pubmed: 23138183 doi: 10.1038/leu.2012.327
McCabe NR, Kipiniak M, Kobayashi H, Thirman M, Gill H, Rowley JD, et al. DNA rearrangements and altered transcripts of the MLL gene in a human T-all cell line karpas 45 with a t(X;II) (q13;q23) translocation. Genes Chromosom Cancer. 1994;9:221–4.
pubmed: 7515665 doi: 10.1002/gcc.2870090311
Hayette S, Tigaud I, Maguer-Satta V, Bartholin L, Thomas X, Charrin C, et al. Recurrent involvement of the MLL gene in adult T-lineage acute lymphoblastic leukemia. Blood. 2002;99:4647–9.
pubmed: 12066788 doi: 10.1182/blood-2002-03-0717
Tanabe S, Zeleznik-Le NJ, Kobayashi H, Vignon C, Espinosa R, LeBeau MM, et al. Analysis of the t(6;11)(q27;q23) in leukemia shows a consistent breakpoint in AF6 in three patients and in the ML-2 cell line. Genes Chromosom Cancer. 1996;15:206–16.
pubmed: 8703846 doi: 10.1002/(SICI)1098-2264(199604)15:4<206::AID-GCC2>3.0.CO;2-5
Peterson JF, Baughn LB, Pearce KE, Williamson CM, Benevides Demasi JC, Olson RM, et al. KMT2A (MLL) rearrangements observed in pediatric/young adult T-lymphoblastic leukemia/lymphoma: a 10-year review from a single cytogenetic laboratory. Genes Chromosom Cancer. 2018;57:541–6.
pubmed: 30203571 doi: 10.1002/gcc.22666
Ferrando AA, Armstrong SA, Neuberg DS, Sallan SE, Silverman LB, Korsmeyer SJ, et al. Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. Blood. 2003;102:262–8. Epub 2003 Mar 13
pubmed: 12637319 doi: 10.1182/blood-2002-10-3221
Rubnitz JE, Camitta BM, Mahmoud H, Raimondi SC, Carroll AJ, Borowitz MJ, et al. Childhood acute lymphoblastic leukemia with the MLL-ENL fusion and t(11;19)(q23;p13.3) translocation. J Clin Oncol. 1999;17:191–6.
pubmed: 10458233 doi: 10.1200/JCO.1999.17.1.191
Chae H, Lim J, Kim M, Park J, Kim Y, Han K, et al. Phenotypic and genetic characterization of adult T-cell acute lymphoblastic leukemia with del(9)(q34);SET-NUP214 rearrangement. Ann Hematol. 2012;91:193–201.
pubmed: 21720744 doi: 10.1007/s00277-011-1289-x
Quentmeier H, Schneider B, Röhrs S, Romani J, Zaborski M, MacLeod RA, et al. SET-NUP214 fusion in acute myeloid leukemia- and T-cell acute lymphoblastic leukemia-derived cell lines. BioMed Central. 2009;2:1–5.
Oka M, Mura S, Otani M, Miyamoto Y, Nogami J, Maehara K, et al. Chromatin-bound CRM1 recruits SET-Nup214 and NPM1c onto HOX clusters causing aberrant HOX expression in leukemia cells. eLife. 2019;8:e46667.
pubmed: 31755865 pmcid: 6874418 doi: 10.7554/eLife.46667
Saito S, Cigdem S, Okuwaki M, Nagata K. Leukemia-Associated Nup214 Fusion Proteins Disturb the XPO1-Mediated Nuclear-Cytoplasmic Transport Pathway and Thereby the NF-κB Signaling Pathway. Mol Cell Biol. 2016;36:1820–35.
pubmed: 27114368 pmcid: 4911740 doi: 10.1128/MCB.00158-16
Vanden Bempt M, Demeyer S, Broux M, De Bie J, Bornschein S, Mentens N, et al. Cooperative Enhancer Activation by TLX1 and STAT5 Drives Development of NUP214-ABL1/TLX1-Positive T Cell Acute Lymphoblastic Leukemia. Cancer Cell. 2018;34:271–.e7.
pubmed: 30107177 pmcid: 6097876 doi: 10.1016/j.ccell.2018.07.007
Burmeister T, Gökbuget N, Reinhardt R, Rieder H, Hoelzer D, Schwartz S. NUP214-ABL1 in adult T-ALL: the GMALL study group experience. Blood. 2006;108:3556–9.
pubmed: 16873673 doi: 10.1182/blood-2006-04-014514
De Keersmaecker K, Graux C, Odero MD, Mentens N, Somers R, Maertens J, et al. Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32). Blood. 2005;105:4849–52.
pubmed: 15713800 doi: 10.1182/blood-2004-12-4897
Schlieben S, Borkhardt A, Reinisch I, Ritterbach J, Janssen JW, Ratei R, et al. Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92. Leukemia. 1996;10:957–63.
pubmed: 8667652
Keersmaecker KD, Porcu M, Cox L, Girardi T, Vandepoel R, Beeck JO de et al. NUP214-ABL1-mediated cell proliferation in T-cell acute lymphoblastic leukemia is dependent on the LCK kinase and various interacting proteins. 2014;99:85–93.
Graux C, Cools J, Melotte C, Quentmeier H, Ferrando A, Levine R, et al. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet. 2004;36:1084–9.
pubmed: 15361874 doi: 10.1038/ng1425
Quintás-Cardama A, Tong W, Manshouri T, Vega F, Lennon PA, Cools J, et al. Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies. Leukemia. 2008;22:1117–24.
pubmed: 18401417 doi: 10.1038/leu.2008.80
Ballerini P, Landman-Parker J, Cayuela JM, Asnafi V, Labopin M, Gandemer V, et al. Impact of genotype on survival of children with T-cell acute lymphoblastic leukemia treated according to the French protocol FRALLE-93: the effect of TLX3/HOX11L2 gene expression on outcome. Haematologica. 2008;93:1658–65.
pubmed: 18835836 doi: 10.3324/haematol.13291
Wasylyk B, Hahn SL, Giovane A. The Ets family of transcription factors. In: Christen P, Hofmann E, editors. EJB Reviews 1993. Berlin, Heidelberg:Springer;1994. p. 7–18.
Klossowski S, Miao H, Kempinska K, Wu T, Purohit T, Kim E, et al. Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia. J Clin Investig. 2020;130:981–97.
pubmed: 31855575 pmcid: 6994154 doi: 10.1172/JCI129126

Auteurs

Thomas Steimlé (T)

Université de Paris (Descartes), Institut Necker-Enfants Malades (INEM), Institut national de la santé et de la recherche médicale (Inserm) U1151, and Laboratory of Onco-Hematology, Assistance Publique-Hôpitaux de Paris, Hôpital Necker Enfants-Malades, Paris, France.

Marie-Emilie Dourthe (ME)

Université de Paris (Descartes), Institut Necker-Enfants Malades (INEM), Institut national de la santé et de la recherche médicale (Inserm) U1151, and Laboratory of Onco-Hematology, Assistance Publique-Hôpitaux de Paris, Hôpital Necker Enfants-Malades, Paris, France.
Department of Pediatric Hematology and Immunology, Robert Debré University Hospital (AP-HP), Université de Paris, Paris, France.

Marion Alcantara (M)

Université de Paris (Descartes), Institut Necker-Enfants Malades (INEM), Institut national de la santé et de la recherche médicale (Inserm) U1151, and Laboratory of Onco-Hematology, Assistance Publique-Hôpitaux de Paris, Hôpital Necker Enfants-Malades, Paris, France.
Department of Pediatric Hematology and Immunology, Robert Debré University Hospital (AP-HP), Université de Paris, Paris, France.
Center for Cancer Immunotherapy, INSERM U932, Institut Curie, PSL Research University, Paris, France.
ORCID: 0000-0002-2912-0343

Aurore Touzart (A)

Université de Paris (Descartes), Institut Necker-Enfants Malades (INEM), Institut national de la santé et de la recherche médicale (Inserm) U1151, and Laboratory of Onco-Hematology, Assistance Publique-Hôpitaux de Paris, Hôpital Necker Enfants-Malades, Paris, France.

Mathieu Simonin (M)

Université de Paris (Descartes), Institut Necker-Enfants Malades (INEM), Institut national de la santé et de la recherche médicale (Inserm) U1151, and Laboratory of Onco-Hematology, Assistance Publique-Hôpitaux de Paris, Hôpital Necker Enfants-Malades, Paris, France.
Department of Pediatric Hematology and Immunology, Robert Debré University Hospital (AP-HP), Université de Paris, Paris, France.
Center for Cancer Immunotherapy, INSERM U932, Institut Curie, PSL Research University, Paris, France.
Department of Pediatric Hematology and Oncology, Assistance Publique-Hôpitaux de Paris (AP-HP), GH HUEP, Armand Trousseau Hospital, Paris, France.
Sorbonne Universités, UPMC Univ Paris 06, UMRS 938, CDR Saint-Antoine, GRC n°07, GRC MyPAC, Paris, France.

Johanna Mondesir (J)

Université de Paris (Descartes), Institut Necker-Enfants Malades (INEM), Institut national de la santé et de la recherche médicale (Inserm) U1151, and Laboratory of Onco-Hematology, Assistance Publique-Hôpitaux de Paris, Hôpital Necker Enfants-Malades, Paris, France.

Ludovic Lhermitte (L)

Université de Paris (Descartes), Institut Necker-Enfants Malades (INEM), Institut national de la santé et de la recherche médicale (Inserm) U1151, and Laboratory of Onco-Hematology, Assistance Publique-Hôpitaux de Paris, Hôpital Necker Enfants-Malades, Paris, France.
ORCID: 0000-0003-2498-0376

Jonathan Bond (J)

Systems Biology Ireland, School of Medicine, University College Dublin, Dublin, Ireland.

Carlos Graux (C)

Department of Hematology, Université catholique de Louvain, CHU UCL Namur - site Godinne, Yvoir, Belgium.

Nathalie Grardel (N)

Laboratory of Hematology, CHRU Lille, Lille, France and U1172, INSERM, Lille, France.

Jean-Michel Cayuela (JM)

Laboratory of Hematology and EA 3518 University Hospital Saint-Louis, AP-HP and Université de Paris, Paris, France.

Isabelle Arnoux (I)

Hematology Laboratory, Marseille University Hospital Timone, Marseille, France.

Virginie Gandemer (V)

Department of Pediatric Hematology and Oncology, University Hospital of Rennes, Rennes, France.

Marie Balsat (M)

Service d'hématologie clinique, Hôpital Lyon Sud, Marseille, France.

Norbert Vey (N)

Aix-Marseille Univ, Inserm, CNRS, Institut Paoli-Calmettes, CRCM, Marseille, France.
ORCID: 0000-0001-7027-040X

Elizabeth Macintyre (E)

Université de Paris (Descartes), Institut Necker-Enfants Malades (INEM), Institut national de la santé et de la recherche médicale (Inserm) U1151, and Laboratory of Onco-Hematology, Assistance Publique-Hôpitaux de Paris, Hôpital Necker Enfants-Malades, Paris, France.
ORCID: 0000-0003-0520-0493

Norbert Ifrah (N)

PRES LUNAM, CHU Angers service des Maladies du Sang et CRCINA INSERM, Angers, France.

Hervé Dombret (H)

Institut de Recherche Saint-Louis, Université de Paris, EA-3518, Paris, France.

Arnaud Petit (A)

Department of Pediatric Hematology and Oncology, Assistance Publique-Hôpitaux de Paris (AP-HP), GH HUEP, Armand Trousseau Hospital, Paris, France.
Sorbonne Universités, UPMC Univ Paris 06, UMRS 938, CDR Saint-Antoine, GRC n°07, GRC MyPAC, Paris, France.
ORCID: 0000-0001-8363-1622

André Baruchel (A)

Department of Pediatric Hematology and Immunology, Robert Debré University Hospital (AP-HP), Université de Paris, Paris, France.
Institut de Recherche Saint-Louis, Université de Paris, EA-3518, Paris, France.

Philippe Ruminy (P)

Inserm U1245, Centre Henri Becquerel, Université de Rouen, IRIB, Rouen, France.

Nicolas Boissel (N)

Institut de Recherche Saint-Louis, Université de Paris, EA-3518, Paris, France.
Inserm U1245, Centre Henri Becquerel, Université de Rouen, IRIB, Rouen, France.
AP-HP, Hôpital Saint Louis, Unité d'Hématologie Adolescents et Jeunes Adultes, Paris, France.

Vahid Asnafi (V)

Université de Paris (Descartes), Institut Necker-Enfants Malades (INEM), Institut national de la santé et de la recherche médicale (Inserm) U1151, and Laboratory of Onco-Hematology, Assistance Publique-Hôpitaux de Paris, Hôpital Necker Enfants-Malades, Paris, France. vahid.asnafi@aphp.fr.
ORCID: 0000-0002-6255-5314

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adolescent › Clinico-biological features of T-cell acute...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Clinico-biological features of T-cell acute...
questionsmedicales.fr › Personnes › Tranches d'âge › Enfant › Clinico-biological features of T-cell acute...
questionsmedicales.fr › Personnes › Tranches d'âge › Enfant › Enfant d'âge préscolaire › Clinico-biological features of T-cell acute...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Clinico-biological features of T-cell acute...
questionsmedicales.fr › Personnes › Tranches d'âge › Nourrisson › Clinico-biological features of T-cell acute...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Clinico-biological features of T-cell acute...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Jeune adulte › Clinico-biological features of T-cell acute...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines tumorales › Protéines oncogènes › Protéines de fusion oncogènes › Clinico-biological features of T-cell acute...
questionsmedicales.fr › Maladies du système immunitaire › Syndromes immunoprolifératifs › Syndromes lymphoprolifératifs › Leucémie lymphoïde › Leucémie-lymphome lymphoblastique à précurseurs B et T › Leucémie-lymphome lymphoblastique à précurseurs T › Clinico-biological features of T-cell acute...
questionsmedicales.fr › Diagnostic › Pronostic › Clinico-biological features of T-cell acute...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Clinico-biological features of T-cell acute...